Improvement of the activity : significant increase of 1st 2022 semester turnover
13 Juli 2022 - 6:00PM
Improvement of the activity : significant increase of 1st 2022
semester turnover
Press release
Ecully,
July
13th 2022
–
6.00pm
Revenue for the first half
2022 : + 65%
- Acceleration of sales over the 2nd
quarter (+74%)
- Higher activity level than before the health crisis
- Very good performances in France and Latin America
In thousands euros |
2022* |
2021* |
Variation 2022/2021in
% |
Turnover 1 st quarter |
1 342 |
866 |
+ 55% |
Turnover 2nd quarter |
1 770 |
1 029 |
+ 74% |
Turnover 1 st
semester |
3 113 |
1 885 |
+ 65% |
CA proforma 1st
semester** |
3 113 |
2 140 |
+ 45% |
* Non audited figures** Non audited pro forma
2021 revenue including, for comparison, Distimp from January 1st,
2021, while the company was acquired on June 25th, 2021.
Committed to a growth trajectory,
Spineway saw its sales accelerate over
the 2nd quarter 2022 to
total turnover of 1,8
M€, an increase of 74% compared to last
year, despite a still fragile and uneven context of recovery in the
areas where it operates. This performance brings revenue for the
first half 2022 to
3,1M€
(+65% compared to S1 2021). This allows the Group to exceed
the turnover of the 1st half 2019 (before the crisis) by 19%, which
amounted to 2,6
M€.
Latin America, the Group's
historic region, remains predominant with a revenue of 1,5 M€ and
sales rising up to 72% in the first half 2022.
The Europe zone, up 106%
compared to S1 2021 with a revenue of 0,9 M€, fully benefits from
the synergies put in place with Distimp, particularly in France,
which is now the Group's second zone.
During the 2nd quarter 2022, the Group also
benefited from good results in the Middle East
area (+96%) and achieved in S1 2022 a turnover of 0,4 M€ in this
zone, up by +171%. compared to 2021.
A dynamic semester driving
growth
Over the semester, the Group was able to
highlight the products resulting from the integration of the
Distimp (1) company, which complement the existing Spineway ranges.
These new ranges now represent 22% of the Group's turnover,
although they have not yet been deployed on all territories. The
historic Mont-Blanc and Mont-Blanc MIS ranges contribute at 57% of
Group sales in the first half 2022.
This good commercial performance
confirms the relevance of the Group's positioning, which is
returning to its best sales levels. Confirmed in its strategy,
combining organic growth and targeted external growth, Spineway
will continue its development in order to position itself as a
European benchmark player in the spine sector.
Upcoming :
July 25th
2022, Extraordinary General
Meeting
SPINEWAY IS ELIGIBLE FOR THE PEA-PME
(EQUITY SAVINGS PLANS FOR SMES) Find out all about
Spineway at www.spineway.com
This press release has been prepared in both
English and French. In case of discrepancies, the French version
shall prevail.
Spineway
designs, manufactures and markets
innovative implants and surgical instruments for treating severe
disordersof the spinal
column.Spineway has an international network of
over 50 independent distributors and 90% of its revenue comes from
exports.Spineway, which is eligible for investment
through FCPIs (French unit trusts specializing in innovation), has
received theOSEO Excellence award since 2011 and
has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent
Innovationaward (2013) – INPI Talent award
(2015).ISIN: FR0011398874 -
ALSPW
Contacts :
SPINEWAYShareholder – service lineAvailable
Tuesday through Thursday (10 am -12 pm)0806 70 60
60 |
Eligible PEA / PMEALSPWEuronext Growth |
AELIUMFinance & CommunicationInvestor
relationsSolène Kennisspineway@aelium.fr |
Presence at the SFCR (French Society of Spinal Surgery) – Press
release of June 24th, 2022
Spineway (EU:ALSPW)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Spineway (EU:ALSPW)
Historical Stock Chart
Von Dez 2023 bis Dez 2024